Clinical Trial Update: Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients With Relapsed and Refractory Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluated the combination of panobinostat and everolimus in relapsed or refractory lymphoma; results from the completed study were posted in 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma

Drugs mentioned

• Everolimus (everolimus)
• Panobinostat (Panobinostat)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2014-09-10